EJC Supplements

Published by: Pergamon-Elsevier Science Ltd  

People

  1. Fleisher
    Fleisher
  2. Sawyers
    Sawyers
  3. Scher
    Scher

Groups

  1. Center for Hematologic Malignancies (1)
  2. Department of Medicine (1)
  3. Executive Committee, Center for Hematologic Malignancies (1)
  4. GSK Faculty (1)
  5. Genitourinary Oncology Service (1)
  6. Hematologic Malignancies, Division of (1)
  7. Human Oncology and Pathogenesis Program (1)
  8. Molecular Imaging and Therapy Service (1)
  9. Molecular Pharmacology and Chemistry Program Faculty (1)
  10. Radiology, Department of (1)
Search Within
  1. "Executive Committee, Center for Hematologic Malignancies"
Formats
  1. Meeting Abstract (1)
Groups
  1. Center for Hematologic Malignancies (1)
  2. Department of Medicine (1)
  3. Executive Committee, Center for Hematologic Malignancies (1)
  4. GSK Faculty (1)
  5. Genitourinary Oncology Service (1)
  6. Hematologic Malignancies, Division of (1)

More Groups

People
  1. Charles Sawyers (1)
  2. Howard Scher (1)
  3. Julia Shelkey (1)
  4. Martin Fleisher (1)
  5. Steven Larson (1)
Years
  1. 2008 (1)
Publishers
  1. Pergamon-Elsevier Science Ltd (1)

Results (1)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I-II study of MDV3100 in castration resistant prostate cancer. The Prostate Cancer Clinical Trials consortium
    Meeting Abstract

    Scher, H.; Beer, T.; Higano, C.; Logothetis, C.; Shelkey, J.; Hung, D.; Hirmand, M.; Larson, S.; Fleisher, M.; Sawyers, C.
    EJC Supplements (2008)

    Fulltext@MSK | Save

    • EJC Supplements – authorized name for:

    Name ISSN / ISBN Publisher
    EJC Supplements 1359-6349 Pergamon-Elsevier Science Ltd
    EJC Supplements 1359-6349 Unknown
    European Journal of Cancer Supplements 1359-6349 Elsevier Inc.
    European Journal of Cancer Supplements 1359-6349 Elsevier Inc.
    European Journal of Cancer Supplements 1359-6349 Pergamon-Elsevier Science Ltd
    European Journal of Cancer, Supplement 13596349 Elsevier Inc.
    European Journal of Cancer, Supplement 13596349 Unknown